⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TVTX News
Travere Therapeutics, Inc. Common Stock
Travere Therapeutics Reports First Quarter 2026 Financial Results
businesswire.com
TVTX
Purespring announces publication of notable study highlighting an under recognised genetic driver of adult-onset FSGS, in particular in US and UK populations
globenewswire.com
TVTX
NTRA
Travere Therapeutics to Report First Quarter 2026 Financial Results
businesswire.com
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
TVTX
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
globenewswire.com
TVTX
LGND
Form 8-K
sec.gov
TVTX
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
businesswire.com
TVTX
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor
globenewswire.com
TVTX
Surge to Save Newborns Coalition Launches with New Study Showing Cost to End State-by-State Newborn Screening Variability
prnewswire.com
TVTX